Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Royal Oak, Michigan 48073


Purpose:

This is a prospective, open-label, Phase 1, single center study evaluating the safety and efficacy of Autologous Muscle Derived Cells as a treatment for chronic Underactive Bladder.


Study summary:

Subject that meet inclusion and exclusion criteria will be consented and enrolled in this study. Initial screening includes blood and urine testing, questionnaires, physical examination, specialized bladder function testing and review of medical history. At the next visit a small sample of each subject's own thigh muscle is obtained by needle biopsy. This cell biopsy is sent to a specialized lab for growth and processing. Approximately ten weeks later the frozen cells will be sent back to the treatment site for thawing, diluting and injection under lighted instrumentation into the subject's bladder wall. The subject will be followed for 6 months and at that time may be eligible for a second injection of cells. The study doctor will determine if the second injection may be beneficial to the subject. All subjects will be followed for up to 12 months. The follow-up assessments at 12 months will include questionnaires, urine and blood testing, specialized bladder function testing and visualizing the inside of the bladder with a lighted instrument.


Criteria:

Inclusion Criteria: 1. Males and females, at least 18 years of age 2. History of Underactive Bladder (UAB) for at least 6 months documented in the medical record 3. Recurring UAB symptoms 4. Subjects unresponsive to relief symptoms of UAB with previous use of medications and/or other treatments 5. Voiding difficulty (complains of difficulty emptying the bladder) 6. Post void residual greater than or equal to 150 mL 7. Total UAB Questionnaire Score greater than or equal to 3 8. Females of child-bearing potential agree to use a reliable form of birth control for the entire study duration 9. Willing and capable of understanding and complying with all requirements of the protocol, including proper completion of the voiding diaries and self-administered questionnaires Exclusion Criteria: 1. Pregnant, plans to become pregnant or lactating 2. History of bleeding diathesis, uncorrectable coagulopathy, or would refuse a blood transfusion 3. Currently on anticoagulant therapy 4. Obvious neurological impairment 5. Known allergy or hypersensitivity to bovine proteins or allergens, gentamicin sulfate, ampicillin, and/or lidocaine that medically warrants exclusion as determined by the physician 6. Simultaneously participating in another investigational drug or device study or use of any investigational drug(s) or therapeutic device(s) within 3 months preceding enrollment 7. Has been treated with an investigational device, drug, or procedure for UAB within the last 6 months. 8. Medical condition or disorder that may limit life expectancy or that may cause protocol deviations (e.g. unable to perform self-evaluations and/or accurately report medical history, urinary symptoms, and/or data) 9. History of cancer in pelvic organs, ureters, or kidneys or any cancer that has undergone treatment within the past 12 months 10. Compromised immune system due to disease state, chronic corticosteroid use, or other immunosuppressive therapy 11. History of radiation therapy to the bladder 12. Tests positive for Hepatitis B (Hepatitis B Surface Antigen), and Anti-Hepatitis B Core Total Antibody, Hepatitis C (Anti-Hepatitis C virus enzyme immunoassay, Human Immunodeficiency Virus (HIV Type I and 2 Antibodies), and/or Syphilis 13. Abnormal renal function 14. An active urinary tract infection as evidenced by positive urine culture 15. Taking medication(s) that affect urination (e.g. medically necessary, stable drugs) such as prescription drugs, over-the-counter drugs, or dietary supplements, including herbal supplements and those taken with teas 16. Requires concomitant use of or treatment with immunosuppressive agents 17. Pelvic organ prolapse beyond the introitus (e.g., cystocele, rectocele) 18. Abnormal bladder capacity (i.e., less than 100 mL)


NCT ID:

NCT02463448


Primary Contact:

Principal Investigator
Jason Gilleran, MD
Beaumont Health


Backup Contact:

N/A


Location Contact:

Royal Oak, Michigan 48073
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.